8-K
BioCryst Reports Third Quarter 2026 Financial Results and Raises Total Revenue Guidance
8-K
BioCryst Reports Second Quarter 2026 Financial Results and Business Updates
8-K/A
Company Plans to Discontinue Discovery Programs, Incurring $6.2-$7.5 Million in Termination and Severance Costs
8-K
BioCryst Shifts to External Innovation Model, Closing Birmingham Research Facility
8-K
BioCryst Pharmaceuticals, Inc. Announces Results of 2026 Annual Meeting of Stockholders
8-K
BioCryst Reports Q1 2026 Financial Results and European Licensing Agreement for Navenibart
